← Back to Search

Thermal Ablation

Focal Laser Ablation for Prostate Cancer

N/A
Waitlist Available
Led By Allan Pantuck, M.D.
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with untreated, organ-confined prostate cancer (clinical stage ≤ T2b, Gleason =7) aged 40 to 85 years
Subjects desire focal therapy and decline conventional treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery, and hormone therapy)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from treatment at 1 week, 1 month, and every 3 months until one year.
Awards & highlights

Study Summary

This trial is testing a new, minimally invasive way to treat prostate cancer using heat. The goal is to see if it is safe and effective.

Who is the study for?
Men aged 40-85 with untreated, organ-confined prostate cancer (clinical stage ≤ T2b, Gleason =7), who have had a recent MRI and biopsy confirming the diagnosis. They should want focal therapy over conventional treatments and have a prostate size between 20cc to 80cc. Excluded are those with bleeding disorders, on anticoagulants that can't be stopped, prior prostate cancer treatments, significant rectal or urinary conditions, or contraindications to MRI.Check my eligibility
What is being tested?
The trial is testing the safety and feasibility of using MR-ultrasound fusion-guided Focal Laser Ablation (FLA) for treating prostate cancer with the Orion System. This method aims at precisely targeting and destroying cancerous tissue in the prostate while sparing healthy areas.See study design
What are the potential side effects?
Potential side effects may include discomfort from the procedure itself, risks associated with laser ablation such as damage to surrounding tissues leading to urinary or sexual dysfunction, infection risk due to transrectal device insertion, and typical adverse reactions related to any invasive treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 to 85 years old with early-stage prostate cancer.
Select...
I prefer targeted treatment over standard prostate cancer treatments.
Select...
My biopsy shows I have a specific type of prostate cancer with a Gleason score of 7.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from treatment at 1 week, 1 month, and every 3 months until one year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from treatment at 1 week, 1 month, and every 3 months until one year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety based on cumulative adverse events incurred

Trial Design

1Treatment groups
Experimental Treatment
Group I: Focal Laser AblationExperimental Treatment1 Intervention
The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Focal Laser Ablation
2015
Completed Early Phase 1
~20

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
359 Previous Clinical Trials
26,065 Total Patients Enrolled
38 Trials studying Prostate Cancer
3,990 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,143 Total Patients Enrolled
560 Trials studying Prostate Cancer
507,163 Patients Enrolled for Prostate Cancer
Allan Pantuck, M.D.Principal InvestigatorUniversity of California at Los Angeles

Media Library

Focal Laser Ablation (Thermal Ablation) Clinical Trial Eligibility Overview. Trial Name: NCT04305925 — N/A
Prostate Cancer Research Study Groups: Focal Laser Ablation
Prostate Cancer Clinical Trial 2023: Focal Laser Ablation Highlights & Side Effects. Trial Name: NCT04305925 — N/A
Focal Laser Ablation (Thermal Ablation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04305925 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment open to participants aged 60 and older?

"This clinical trial has stipulated that only those aged 40 to 85 are eligible. For younger patients, there are 76 different studies available, while older individuals have access to 1315 distinct trials."

Answered by AI

Are there any current openings for participants in this experiment?

"According to the details published on clinicaltrials.gov, this particular research project is no longer recruiting patients; it was initially posted on March 16th 2020 and last edited in December 3rd 2021. At present, however, there are 1,321 other trials actively seeking participants."

Answered by AI

Are the qualifications for this experiment compatible with my background?

"This study's eligibility requirements stipulate that participants must be 40-85 years of age and have untreated, localized prostate cancer (Gleason =7). Furthermore, the enrollees should prefer focal therapy over conventional treatments such as active surveillance, radical prostatectomy, radiation therapy, cryosurgery or hormone therapy."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Focal Laser Ablation of Prostate Cancer
2020. "Focal Laser Ablation of Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04305925.
All > Mens Health
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top